Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

AMNEAL PHARMACEUTICALS, INC. (AMRX) vs Lantheus Holdings, Inc. (LNTH)

AMNEAL PHARMACEUTICALS, INC. and Lantheus Holdings, Inc. are both Drug Manufacturers Specialty & Generic companies. AMNEAL PHARMACEUTICALS, INC. and Lantheus Holdings, Inc. are of similar size ($6.5B and $6.3B). Lantheus Holdings, Inc. trades at the lower P/E: 23.7× against 39.5×. AMNEAL PHARMACEUTICALS, INC. grew revenue faster over the last twelve months: 9.28% against 2.35%. Lantheus Holdings, Inc. has the higher net margin (17.7% vs 5.05%) and the higher return on invested capital (14.7% vs 11.1%). Across the 21 metrics below, Lantheus Holdings, Inc. leads on 16 and AMNEAL PHARMACEUTICALS, INC. on 5.

Valuation

Metric AMRX LNTH Drug Manufacturers Specialty & Generic median
P/E 39.54 23.69 20.14
P/S 2.02 4.18 2.25
P/B 191.09 4.95 1.90
Price to free cash flow n/m 16.54 16.54
EV/EBITDA 13.30 16.38 12.29
EV/Sales 2.84 4.16 2.56
Earnings yield 2.53% 4.22% (2.99%)
Free cash flow yield (0.18%) 6.04% 0.00%

Profitability

Metric AMRX LNTH Drug Manufacturers Specialty & Generic median
Gross margin 39.32% 60.14% 53.94%
Operating margin 14.56% 19.43% 0.00%
Net margin 5.05% 17.69% 0.00%
Free cash flow margin (0.37%) 25.24% 0.00%
Return on equity (395.84%) 22.21% (0.40%)
Return on assets 4.37% 12.15% (3.32%)
Return on invested capital 11.05% 14.65% 0.00%

Growth

Metric AMRX LNTH Drug Manufacturers Specialty & Generic median
Revenue growth (TTM) 9.28% 2.35% 10.01%
EPS growth (last fiscal year) 157.89% (21.79%) —
Revenue growth, 5-year CAGR 8.66% 35.35% 6.74%
Net income growth, 5-year CAGR (4.57%) 0.00% 0.00%

Health

Metric AMRX LNTH Drug Manufacturers Specialty & Generic median
Debt to equity 80.86 0.44 0.05
Current ratio 2.20 3.06 2.31
Net debt to EBITDA 3.62 0.55 0.85

Dividend

Metric AMRX LNTH Drug Manufacturers Specialty & Generic median
Dividend yield 0.27% — 1.70%
Payout ratio 0.00 0.00 0.00

Size

Metric AMRX LNTH Drug Manufacturers Specialty & Generic median
Market cap 6.32b 6.51b 337.35m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack